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Arginase in glomerulonephritis. l-Arginine is converted to ni- examined. There appeared to be an increase in ornithine
tric oxide and citrulline by the enzyme nitric oxide synthase decarboxylase at six hours and a delayed increase in
(NOS). Its in vivo inhibition has led to the revelation of a ornithine aminotransferase, between days 3 and 21 [3].multitude of diverse, often conflicting functions in the inflam-
After injection of lipopolysaccharide (LPS) in rats, NOSmatory melee. l-Arginine is also converted to ornithine and
II and Arginase I mRNA were co-induced within 12urea by the enzyme arginase as a part of the hepatic urea cycle.
However, a more holistic interpretation of the two pathways hours [4]. In contrast, in a model of sepsis, increased
and the associated metabolism (summarized in Fig. 1) has led expression of NOS II was associated with a loss of Argi-
to its reassessment as a pathologically significant enzyme. This nase II expression in lung tissue [5].is reflected by the continued increase over the past five years
of the number of publications discussing both nitric oxide and
Arginine-metabolizing pathways reciprocally inhibitarginase. The strong association between inflammation and
each other in vitrohigh arginase and NOS activity is epitomized by immune com-
plex-induced glomerulonephritis and other glomerulonephriti- These pathways have been shown to inhibit each other
des. Arginase is encoded by two recently discovered genes
at multiple levels, including substrate competition and(Arginase I and Arginase II). There is now substantial evidence
protein and mRNA stability and expression.for an interaction between both arginase isoforms and all three
NOS isoforms in pathological situations. This review considers NOS inhibits arginase. Glomeruli were isolated from
the relationship between Arginases I and II and the inflamma- normal rats and nephritic rats four days after the induc-
tion-associated isoform of NOS called NOS II. In particular, tion of accelerated nephrotoxic nephritis. Addition of theit consolidates the current understanding of arginase and asso-
NOS inhibitor NG-monomethyl-l-arginine (L-NMMA)ciated metabolic pathways, and highlights some of the issues
substantially increased metabolism of arginine by argi-that are often overlooked in such studies.
nase over the 48-hour period of culture [6]. Limitation
of l-arginine flux through the arginase pathway by NOS
WHAT IS KNOWN ABOUT ARGINASE AND ITS
is likely the result of two independent mechanisms. The
ASSOCIATED METABOLISM?
first is competition for substrate, discussed later. The
Enzymes associated with arginine metabolism are second is inhibition of arginase by N-hydroxy-l-argi-
up-regulated at inflammatory sites nine, an intermediate in the conversion of arginine to
For example, NOS II and Arginase I have been shown NO. This has been shown to be secreted into the culture
to be up-regulated in glomeruli after induction of heter- supernatant of LPS-stimulated rabbit alveolar macro-
ologous nephrotoxic nephritis [1]. A similar increase in phages and has been shown to increase from 4 to 16
arginase activity and induction of NOS II was observed mol/L in the plasma of LPS-treated rats [7]. In 1994
in in situ glomerulonephritis [2], and accelerated nephro- Boucher and colleagues demonstrated potent inhibition
toxic nephritis [3]. These results were confirmed by Ket- of macrophage arginase by N-hydroxy-l-arginine [8].
teler et al, who studied arginine metabolism in isolated This compound also inhibited arginase activity in ne-
glomeruli from rats with anti-thymocyte serum-induced phritic glomeruli and in stimulated mesangial cells [6].
glomerulonephritis. At day 1, there was a transient maxi- Another possible mechanism by which NOS activity
mum of nitrite production, whereas arginase activity was might affect arginase activity is through the accumulation
sustained until day 3 of the disease. Ornithine decarbox- of nitrite, a breakdown product of NO. Hraba´k, Bajor and
ylase and ornithine aminotransferase, enzymes leading Temesi demonstrated significant inhibition of inducible
to polyamine and proline production, respectively, were nitric oxide synthase (iNOS) in macrophage lysates, but
not whole cells, by nitrite, with a Km of 4.9 mmol/L [9].
A third product of NOS metabolism, citrulline, hasKey words: arginase, nitric oxide, arginine, glomerulonephritis, kidney,
inflammation. been shown to inhibit arginase activity. Shearer and co-
workers showed that inhibition of arginase activity dur- 2002 by the International Society of Nephrology
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Fig. 1. Arginine and associated metabolic
pathways. (1) argininosuccinate lyase; (2) argi-
nine transporters; (3) arginine decarboxylase;
(4) l-arginine:glycine amidinotransferase; (5)
arginine-tRNA synthetase; (6) arginase; (7)
nitric oxide synthase; (8) ornithine decarbox-
ylase; (9) ornithine aminotransferase; (10) or-
nithine transcarbamylase.
ing increased iNOS activity was unlikely to be due to lower NO production [20]. Macrophages transfected
with Arginase promoted growth of breast tumor cells insubstrate competition. However, they showed that LPS
increased intracellular citrulline concentrations above co-culture systems. This effect was down-regulated by
the arginase inhibitor l-norvaline [21]. In contrast, Argi-100mol/L, a concentration found to significantly inhibit
arginase activity in macrophage lysates [10]. nase I transfection of RAW 264.7 macrophages increased
the efferent pathways but did not affect NO productionArginase inhibits NOS. Evidence that arginase could
inhibit the cytotoxic effects of macrophages via NO was [22]. There is also some in vivo evidence for inhibition
of NO production by arginase. For example, diabeticfirst provided by Hibbs, Vavrin and Taintor [11]. A simi-
lar effect was seen in glomerular cultures. NO is gener- tissue in the corpus cavernosum had reduced ability to
convert l-arginine to l-citrulline. This was reversed byated by nephritic glomeruli isolated 24 hours after induc-
tion of accelerated nephrotoxic nephritis; the addition addition of the arginase inhibitor 2(S)-amino-6-boron-
hexanoic acid (ABH) [23]. In a model of experimentalof arginase to these cultures completely abrogated its
production [12]. trypanosomiasis, macrophages from infected mice have
increased arginase activity. Addition of arginase inhibi-The Km of arginase for l-arginine is reported to be
around 7 to 18 mmol/L [13], whereas that of iNOS is tors restored trypanosome killing in vitro. Injection of
arginine into the peritoneal cavity of infected mice in-3 to 9 mol/L and 130 mol/L for purified and intact
macrophage enzyme activity, respectively [14–16]. The creased NO production and parasite killing, an effect
reversed by addition of L-NMMA [24].concentration of arginine in rat plasma is around 250
mol/L, and therefore, ornithine production by arginase An additional mechanism by which arginase activity
inhibits NO production is through urea generation. NOwill be affected by variations around this level, whereas
the arginine concentration should, in theory, drop con- production in RAW 264.7 macrophages was found to be
inhibited by 10 mmol/L urea, a concentration similar tosiderably before NO production is affected [17]. Modo-
lell and colleagues provided evidence supporting this that found in uremic humans [25].
Cross-inhibition of other pathways. Several other mech-statement [18]. Mouse bone marrow-derived macro-
phages were stimulated with interleukin-4 (IL-4) for 24 anisms of cross-inhibition have been described. NO has
been shown to inhibit ornithine decarboxylase in thehours, after which LPS was added and the culture contin-
ued for a further 24 hours. Cells cultured in medium MCT kidney tubule cell line [26] and in vascular smooth
muscle cells [27]. Inactivation of ornithine decarboxylasecontaining 400 mol/L arginine had large amounts of
arginase but did not generate NO in response to LPS, in has been shown to occur by specific S-nitrosylation of
the enzyme [28].contrast to high NO output in 2000 mol/L. The authors
concluded that arginase was depriving NOS of its sub- Agmatine has been shown to attenuate polyamine syn-
thesis by inhibition of ornithine decarboxylase and alsostrate [18]. Corroborative observations were made by
Chang, Liao and Kuo, who examined these enzyme inter- by suppression of the putrescine transporter. Agmatine
aldehyde, a metabolite of agmatine, has been shown toactions in J774A.1 mouse macrophages [19]. Cells were
cultured for 12 hours in different concentrations of l-argi- be an inhibitor of iNOS in vitro and in vivo. It is likely
that these effects are responsible for the inhibition ofnine. The arginase inhibitor l-norvaline increased NO
production by 55% and 28% at 0.05 mmol/L and 0.1 cell proliferation and improvement in renal function in
thymocyte-1 (Thy-1) glomerulonephritis [29].mmol/L l-arginine, respectively. Outside this range of
arginine concentrations, l-norvaline had no effect. Conversely, polyamines have been shown to inhibit
NO production. Szabo´ and colleagues studied the affectRecently, elegant experiments have been performed
using gene delivery technology. Endothelial cells trans- of polyamines and polyamine derivatives on NO produc-
tion in LPS-stimulated J774.2 macrophages finding that,fected with Arginase I or Arginase II had significantly
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in order of decreasing potency, spermine, spermidine, Arginine-associated enzymes undergo
temporal regulationputrescine and cadaverine inhibited nitrite production
in culture. The inhibitory action of polyamines on iNOS Albina and colleagues first demonstrated temporal
appeared to depend on the presence of spermine oxidase variation in the activity of NOS II and arginase in a rat
[30]. Hraba´k and colleagues examined the effect of vari- wound model of implanted polyvinyl sponges. Over the
ous inhibitors on iNOS activity in rat macrophage lysates first 12 hours, NOS activity prevailed. From 12 hours to
[15]. Putrescine inhibited iNOS activity with a Ki of 0.7 three days, the NOS activity rapidly decreased and the
mmol/L; l-ornithine was also a weak inhibitor. Blachier, arginine concentration rose. From three to ten days, the
arginine concentration fell slowly as wound fluid arginaseMignon and Soubrane analyzed iNOS activity in homog-
increased. Disappearance of NOS activity by three daysenates of livers from rats given LPS [31]. NO production
could not be explained by a dearth of arginine, as culturewas significantly inhibited by spermine at 150 mol/L
of sponges in high-arginine medium did not elicit nitriteand 500 mol/L, but by putrescine and spermidine only
or citrulline synthesis [39, 40].at the higher concentration. Sooranna and Das showed
Cook and co-workers reported a similar pattern ofthat putrescine significantly inhibited nitrite production
enzyme activity [41]. Glomeruli were isolated from theby cultures of the choriocarcinoma cell line BeWo [32].
kidneys of rats with acute in situ glomerulonephritis.
NOS II activity was induced and arginase activity wasArginase activity can modulate efferent pathways
increased in nephritic glomeruli at days 1, 4 and 7, com-Many studies have provided circumstantial evidence
pared to normal glomeruli. Whereas the greatest NOSthat arginase activity may be rate-limiting for the produc-
activity was at 24 hours, arginase activity peaked at fourtion of proline and polyamines. In a physiological con-
days; the activity of both fell rapidly from four to seventext, up-regulation of Arginase II was found to coincide
days. These results were confirmed by Ketteler et al,
with development of connective tissue (rich in proline)
who studied arginine metabolism in isolated glomeruli
in Xenopus laevis [33]. In the lactating mammary gland, from rats with anti-thymocyte serum-induced glomerulo-
a concerted increase in arginase, ornithine aminotrans- nephritis [3]. At day 1, there was a transient maximum
ferase and ornithine decarboxylase was consistent with of nitrite production, whereas arginase activity was sus-
the increased production of proline and polyamines tained until day 3 of the disease. Ornithine decarboxylase
[34, 35]. A pathological up-regulation of these three and ornithine aminotransferase, enzymes leading to
enzymes also was observed in anti-thymocyte serum- polyamine and proline production, respectively, were
induced glomerulonephritis [3]. examined. There appeared to be an increase in ornithine
Harder evidence has been provided by in vitro studies. decarboxylase at six hours and a delayed increase in
Transfecting RAW cells with Arginase I increased polya- ornithine aminotransferase between days 3 and 21.
mine synthesis [22] (with no effect on NO). Transfecting
There is an underlying pattern to expression of theseendothelial cells with Arginase I and Arginase II in-
enzyme systemscreased proline and polyamine synthesis and decreased
The prevailing view is that NOS II and arginase char-NO production [20]. In a similar study, transfecting vas-
acterize, and are inherent to, distinct phases of the in-cular smooth muscle cells with Arginase I or treating
flammatory process. Early flux of arginine through NOSthem with IL-4 resulted in increased urea and polyamine
II is associated with cytotoxicity, promotion of apoptosisproduction and cellular proliferation [27]. The trans-
[42] and nitrosylation of structural components includingforming growth factor- (TGF-)–induced increase in
basement membrane. In the aforementioned studies onputrescine and l-proline generation by vascular smooth
implanted sponge models, the authors proposed thatmuscle cells were profoundly inhibited by the arginase
NOS activity, probably from neutrophils, would contrib-inhibitor HOArg [36]. Buga and colleagues demon-
ute to microbiostasis and vasodilation in the early wound
strated that inhibition of arginase by HOArg retarded
[39, 40].
Caco-2 tumor cell proliferation. Since this effect was In contrast, the delayed flux of arginine through argi-
reversed by the addition of ornithine, putrescine, spermi- nase is linked to cell proliferation via polyamine synthe-
dine or spermine, arginase appeared to be required by sis [27, 43], collagen synthesis [36, 44] and moderation
these cells to synthesize polyamines for optimal cell of apoptosis [45]. For example, TGF- increases fibrosis
growth [37]. Durante et al demonstrated that the polar and wound repair as well as orchestrates the up-regula-
phospholipid lysophosphatidylcholine increases arginase tion of a whole armature of arginine metabolism includ-
activity, arginine uptake and putrescine production of ing arginase, ornithine aminotransferase and collagen
smooth muscle. The arginase inhibitor HOArg was [36]. In contrast, TGF- down-regulates iNOS induction
shown to strongly inhibit putrescine production in cells in rat renal mesangial cells [46] as well as many other
cell types.[38].
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Recently, it has been suggested that NOS II and argi- CAVEATS
nase activity are intrinsic to the T-helper 1 and 2 cell There are several issues that often have been omitted
(Th1 and Th2) immune responses, respectively. As the from discussion in studies on arginine metabolism, espe-
Th1/Th2 dichotomy of murine CD4 T cells became cially in in vivo models.
more widely accepted, interest in regulation of arginine
Arginase activity may be increased systemicallymetabolism by cytokines secreted by these subsets in-
creased. Th1 cells produce interferon- (IFN-), whereas There are three separate points to consider. The first
Th2 cells generate IL-4 and IL-10. Following evidence is that local inflammation may lead to increased arginase
that IL-4 and IL-10 strongly suppressed the induction of activity elsewhere. For example, examination of the
iNOS [47, 48], Modolell and Corraliza demonstrated spleens of mice 12 to 48 hours following surgical trauma
their effect on arginase activity in cell lysates of bone revealed increased Arginase I mRNA and protein ex-
pression and arginase activity with no effect on Arginasemarrow-derived murine macrophages [18, 49]. They de-
II or NOS II mRNA [52]. The same group also observedmonstrated an increase in cellular arginase content when
an increase in renal arginase activity [53].macrophages were cultured with IL-4 and IL-10. These
The second point pertains to the effect of arginase onresults lent credibility to the hypothesis that Th2 cyto-
immune function at sites distal to the site of inflamma-kines were not simply reducing macrophage activation
tion. There is conflicting evidence suggesting that argi-but inducing an alternative phenotype. In subsequent
nase can both inhibit [54] and promote [55] lymphocytestudies, macrophages were cultured with Th1 or Th2 cell
proliferation. Ha¨cker-Shahin and Dro¨ge injected spleenclones, or with in vitro polarized Th1 or Th2 cells. Both
cells from one strain of mouse into the peritoneal cavitysystems showed the same pattern; Th1 and Th2 cells
of another [56]. Spleen cells were isolated from theseexclusively induced iNOS and arginase, respectively. Ar-
responder mice and tested for their immunological re-ginase was induced to a far greater extent than with Th2
sponse to spleen cells of the donor strain (mixed leuko-cytokines alone, and supernatant from Th2 cells also
cyte reaction). Both putrescine and ornithine augmentedinduced arginase. Antibodies against IL-4 and IL-10 sub-
the immunogenicity of the cells to the same extent.stantially abrogated the stimulatory effect of the super-
Therefore, independently of the local inflammation, thenatant on arginase activity [50]. Recently, it has been
systemic immune response may be subject to regulationshown that this phenotypic dichotomy also extends to
by arginine concentrations. This point should be consid-murine macrophages independently of the effect of
ered when systemically administering compounds thatT- or B-lymphocytes. C57Bl/6 mice and BALB/c mice
modulate activity of arginine-associated enzymes.are prototypical Th1 and Th2 strains, respectively; mac-
This leads to the third point, that the sum of systemic
rophages from C57Bl/6 NUDE or SCID mice and
activity of arginase and other arginine-associated en-
BALB/c NUDE or SCID mice demonstrated their re-
zymes will influence plasma amino acid levels. For exam-
spective Th1 and Th2 phenotypes even in the absence ple, one day after induction of accelerated nephrotoxic
of T or B lymphocytes [51]. nephritis, plasma arginine levels were significantly re-
We have observed similar characteristics in isolated duced compared to normal rats [12]. These concentra-
glomeruli and mesangial cells. Four days after induction tions are likely to affect the concentrations at the in-
of accelerated nephrotoxic nephritis, addition of IL-4 flammatory site as well as in distal organs.
caused a large increase in arginase activity in glomerular
cultures independent of the profound decrease in NOS The use of specific NOS inhibitors may cross-inhibit
activity over the 48-hour culture period [6]. The same other enzymes or enzyme systems
observations were made on glomeruli isolated seven days These enzymes, by virtue of their metabolic proximity,
after the induction of disease (unpublished data). When act on molecules possessing similar structural character-
isolated mesangial cells were stimulated with a combina- istics. For example, the NOS inhibitors L-NIO and
tion of cyclic adenosine 3,5-monophosphate (cAMP) L-NMMA inhibit uptake of arginine in endothelial cells
and IL-1, IL-4 exerted the same effect of independently [57] since they are transported by the same cationic y
increasing arginase activity and inhibiting NOS activity. transporter system as l-arginine [58]. A similar effect
This was accompanied by an increase in cell lysate argi- was demonstrated in rat renal brush border membrane
nase activity [6]. iNOS and Arginase I mRNA were unde- vesicles [59]. L-NMMA also was shown to inhibit arginase
tectable in unstimulated glomeruli whereas Arginase II activity in rat macrophages, most likely by inhibition of
mRNA was detectable. iNOS and Arginase I mRNA arginine uptake [60].-Difluoromethylornithine (DFMO)
were induced by the cAMP agonist cholera toxin. Addi- is considered to be a potent ornithine decarboxylase
tion of IL-4 increased expression of Arginase I mRNA inhibitor, however, it also has been shown to inhibit
arginase activity [61]. Many novel inhibitors of arginaseand abolished expression of iNOS mRNA [1].
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